SAB Biotherapeutics (SABS) Other Non-Current Liabilities (2021 - 2026)

SAB Biotherapeutics' Other Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $6.1 million for Q1 2026.

• Quarterly Other Non-Current Liabilities rose 352.0% year-over-year to $6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.1 million (up 352.0% YoY) and the FY2025 annual result came in at $5.6 million, down 11.8% from the prior year.
• Other Non-Current Liabilities was $6.1 million for Q1 2026 at SAB Biotherapeutics, up from $5.6 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $11.8 million in Q4 2023 and bottomed at $8344.0 in Q1 2023.
• A 5-year average of $3.3 million and a median of $2.4 million in 2025 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Other Non-Current Liabilities plunged 99.71% — and 2024, when it soared 75475.46%.
• SAB Biotherapeutics' Other Non-Current Liabilities stood at $320930.0 in 2022, then surged by 3568.79% to $11.8 million in 2023, then slumped by 45.74% to $6.4 million in 2024, then decreased by 11.8% to $5.6 million in 2025, then advanced by 8.56% to $6.1 million in 2026.
• Business Quant data shows SABS's Other Non-Current Liabilities at $6.1 million in Q1 2026, $5.6 million in Q4 2025, and $2.4 million in Q3 2025.